Population impact of lung cancer screening in the United States: Projections from a microsimulation model

English version České info

Chung Yin Kong and colleagues model the health outcomes of lung cancer screening in the US and account for reduced levels of smoking. The benefits of screening and mortality reduction will start to decline in 5 years because of reduced smoking.

Vyšlo v časopise: Population impact of lung cancer screening in the United States: Projections from a microsimulation model. PLoS Med 15(2): e32767. doi:10.1371/journal.pmed.1002506
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002506

Souhrn

Zdroje

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi: 10.3322/caac.21332 26742998.

2. Boer R, Moolgavkar SH, Levy DT. Chapter 15: Impact of tobacco control on lung cancer mortality in the United States over the period 1975-2000—summary and limitations. Risk Anal. 2012;32 Suppl 1:S190–201. doi: 10.1111/j.1539-6924.2012.01827.x 22882889; PubMed Central PMCID: PMC3430975.

3. Wender R, Fontham ET, Barrera E Jr., Colditz GA, Church TR, Ettinger DS, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63(2):107–17. doi: 10.3322/caac.21172 23315954; PubMed Central PMCID: PMC3632634.

4. International Early Lung Cancer Action Program I, Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355(17):1763–71. doi: 10.1056/NEJMoa060476 17065637.

5. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418–29. doi: 10.1001/jama.2012.5521 22610500; PubMed Central PMCID: PMC3709596.

6. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi: 10.1056/NEJMoa1102873 21714641; PubMed Central PMCID: PMC4356534.

7. Moyer VA, Force USPST. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330–8. doi: 10.7326/M13-2771 24378917.

8. Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2010;51(8):957–62. Epub 2010/09/10. doi: 10.1086/656416 20825305; PubMed Central PMCID: PMC2943990.

9. Services CfMM. Decision memo for screening for lung cancer with low dose computed tomography. 2015. Available from: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274

10. McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, et al. Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling. PLoS ONE. 2014;9(6):e99978. Epub 2014/07/01. doi: 10.1371/journal.pone.0099978 24979231; PubMed Central PMCID: PMC4076275.

11. de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):311–20. doi: 10.7326/M13-2316 24379002; PubMed Central PMCID: PMC4116741.

12. Ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. J Epidemiol Community Health. 2015;69(11):1035–9. doi: 10.1136/jech-2014-204079 26071497; PubMed Central PMCID: PMC4978857.

13. Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, et al. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer. 2017;140(11):2436–43. doi: 10.1002/ijc.30602 28073150; PubMed Central PMCID: PMC5516788.

14. Holford TR, Ebisu K, McKay L, Oh C, Zheng T. Chapter 12: Yale lung cancer model. Risk Anal. 2012;32 Suppl 1:S151–65. doi: 10.1111/j.1539-6924.2011.01754.x 22882886; PubMed Central PMCID: PMC3662537.

15. Holford TR, Clark L. Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control. Risk Anal. 2012;32 Suppl 1:S39–50. doi: 10.1111/j.1539-6924.2011.01759.x 22882891; PubMed Central PMCID: PMC3490210.

16. Holford TR, Meza R, Warner KE, Meernik C, Jeon J, Moolgavkar SH, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964–2012. JAMA. 2014;311(2):164–71. doi: 10.1001/jama.2013.285112 24399555; PubMed Central PMCID: PMC4056770.

17. Holford TR, Levy DT, McKay LA, Clarke L, Racine B, Meza R, et al. Patterns of birth cohort-specific smoking histories, 1965–2009. Am J Prev Med. 2014;46(2):e31–7. doi: 10.1016/j.amepre.2013.10.022 24439359; PubMed Central PMCID: PMC3951759.

18. McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology. 2008;248(1):278–87. Epub 2008/05/07. doi: 2481071446 [pii] doi: 10.1148/radiol.2481071446 18458247.

19. McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Tramontano AC, et al. Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal. 2012;32 Suppl 1:S117–24. Epub 2012/08/29. doi: 10.1111/j.1539-6924.2011.01652.x 22882882; PubMed Central PMCID: PMC3478757.

20. McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, et al. Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer. 2008;113(12):3440–9. doi: 10.1002/cncr.23962 18988293; PubMed Central PMCID: PMC2782879. NIHMSID: NIHMS74571.

21. McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology 2008;248(1):278–87. PubMed Central PMCID: PMCAccepted for publication Jan. 30, 2008; not subject to the NIH Public Access Policy. doi: 10.1148/radiol.2481071446 18458247

22. Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, et al. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer. 2014;120(11):1713–24. doi: 10.1002/cncr.28623 24577803; PubMed Central PMCID: PMC4031303.

23. Population Projections [Internet]. United States Census Bureau. 2017. Available from: https://www.census.gov/programs-surveys/popproj.html

24. Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT. Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation. Risk Anal. 2012;32 Suppl 1:S51–68. doi: 10.1111/j.1539-6924.2011.01775.x 22882892; PubMed Central PMCID: PMC3478148.

25. Kinsinger LS, Anderson C, Kim J, Larson M, Chan SH, King HA, et al. Implementation of Lung Cancer Screening in the Veterans Health Administration. JAMA Intern Med. 2017;177(3):399–406. doi: 10.1001/jamainternmed.2016.9022 28135352.

26. Lam VK, Miller M, Dowling L, Singhal S, Young RP, Cabebe EC. Community low-dose CT lung cancer screening: a prospective cohort study. Lung. 2015;193(1):135–9. doi: 10.1007/s00408-014-9671-9 25503535.

27. Duong DK, Shariff-Marco S, Cheng I, Naemi H, Moy LM, Haile R, et al. Patient and primary care provider attitudes and adherence towards lung cancer screening at an academic medical center. Prev Med Rep. 2017;6:17–22. doi: 10.1016/j.pmedr.2017.01.012 28210538; PubMed Central PMCID: PMC5304233.

28. Clarke TC, Soler-Vila H, Fleming LE, Christ SL, Lee DJ, Arheart KL. Trends in Adherence to Recommended Cancer Screening: The US Population and Working Cancer Survivors. Front Oncol. 2012;2:190. doi: 10.3389/fonc.2012.00190 23293767; PubMed Central PMCID: PMC3530735.

29. Patz EF Jr., Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA internal medicine. 2014;174(2):269–74. doi: 10.1001/jamainternmed.2013.12738 24322569; PubMed Central PMCID: PMC4040004.

30. Tramontano AC, Sheehan DF, McMahon PM, Dowling EC, Holford TR, Ryczak K, et al. Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study. BMJ open. 2016;6(2):e010227. Epub 2016/03/02. doi: 10.1136/bmjopen-2015-010227 26928026; PubMed Central PMCID: PMC4780060.

31. Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975–2000. J Natl Cancer Inst. 2012;104(7):541–8. doi: 10.1093/jnci/djs136 22423009; PubMed Central PMCID: PMC3317881.

32. Meza R, Meernik C, Jeon J, Cote ML. Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. PLoS ONE. 2015;10(3):e0121323. doi: 10.1371/journal.pone.0121323 25822850; PubMed Central PMCID: PMC4379166.

33. Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20(4):417–35. doi: 10.1007/s10552-008-9256-0 19002764; PubMed Central PMCID: PMC2711979.

34. Patel MI, Wang A, Kapphahn K, Desai M, Chlebowski RT, Simon MS, et al. Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. J Clin Oncol. 2016;34(4):360–8. doi: 10.1200/JCO.2015.63.5789 26700122; PubMed Central PMCID: PMC4872034.

35. Underwood JM, Townsend JS, Tai E, Davis SP, Stewart SL, White A, et al. Racial and regional disparities in lung cancer incidence. Cancer. 2012;118(7):1910–8. doi: 10.1002/cncr.26479 21918961.

36. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005. doi: 10.1056/NEJMoa1206809 23171096.

37. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e78S–e92S. doi: 10.1378/chest.12-2350 23649455; PubMed Central PMCID: PMC3749713.

38. Marshall HM, Bowman RV, Yang IA, Fong KM, Berg CD. Screening for lung cancer with low-dose computed tomography: a review of current status. J Thorac Dis. 2013;5 Suppl 5:S524–39. doi: 10.3978/j.issn.2072-1439.2013.09.06 24163745; PubMed Central PMCID: PMC3804881.

39. Piana R. The Ongoing Challenges of Lung Cancer Screening. The ASCO Post. 2017 May 25, 2017.